Weak Q3 For Biocon, All Eyes On Biosimilars Approval Flow
Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.
Biocon reported a decline in profits for the third quarter but recent regulatory wins and advancements for its biosimilars portfolio could potentially bring an uptick in growth going forward.